Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (6946)	8/21/2002 6:18:12 PM
From: Hank	Read Replies (2) \| Respond to of 52153

"If these trials are successfull then Tarceva is a $500m plus cancer drug and its 5-10x from here." You should keep in mind the fact that Tarceva was co-developed with Pfizer and subsequentley turned over to OSI after Pfizer and OSI decided to end their cancer discovery collaboration. I am sure Pfizer still has a piece of Tarceva (and admittedly I don't know how much) and this should be considered when trying to estimate future revenue.